Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

被引：0
|
作者：
T. Korkmaz
S. Seber
U. Kefeli
E. Sari
M. Canhoroz
B. Oven
E. Yildirim
N. Yasar
D. Aydin
O. Balvan
N. Sener
S. Yuksel
A. Mert
O. Polat
F. Yumuk
O. Kanat
M. Gumus
N. S. Turhal
机构：
[1] Dr. Lutfi Kirdar Kartal Education and Research Hospital,Department of Medical Oncology
[2] Marmara University Hospital,Medical Oncology Department
[3] Uludag University Hospital,Medical Oncology Department
[4] Marmara University Hospital,Internal Medicine Department
来源：
Clinical and Translational Oncology | 2013年 / 15卷
关键词：
Platinum sensitive disease; Platinum refracter disease; Second-line chemotherapy; Small cell lung cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：535 / 540
页数：5
相关论文
共 50 条
  • [31] Prognostic Factors for Second-line Treatment of Advanced Non-small-cell Lung Cancer: Retrospective Analysis at a Single Institution
    Inal, Ali
    Kaplan, M. Ali
    Kucukoner, Mehmet
    Urakci, Zuhat
    Karakus, Abdullah
    Isikdogan, Abdurrahman
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (04) : 1281 - 1284
  • [32] Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
    Melosky, B.
    Agulnik, J.
    Assi, H.
    CURRENT ONCOLOGY, 2008, 15 (06) : 279 - 285
  • [33] Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis
    Wang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: A review
    Huisman, C
    Smit, EF
    Giaccone, G
    Postmus, PE
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (21) : 3722 - 3730
  • [35] Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis
    Yi, Yanjiao
    Liu, Zining
    Fang, Lihua
    Li, Jianzhong
    Liu, Wenjian
    Wang, Fuxia
    Fu, Ping
    Xie, Chao
    Liu, Jie
    Song, Bao
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 86 (01) : 65 - 74
  • [36] Comparison between single-agent and combination chemotherapy as second-line treatment for advanced non-small cell lung cancer: a multi-institutional retrospective analysis
    Yanjiao Yi
    Zining Liu
    Lihua Fang
    Jianzhong Li
    Wenjian Liu
    Fuxia Wang
    Ping Fu
    Chao Xie
    Jie Liu
    Bao Song
    Cancer Chemotherapy and Pharmacology, 2020, 86 : 65 - 74
  • [37] Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer
    Krug, Lee M.
    Crawford, Jeffrey
    Ettinger, David S.
    Shapiro, Geoffrey I.
    Spigel, David
    Reiman, Tony
    Temel, Jennifer S.
    Michelson, Glenn C.
    Young, Donald Y.
    Hoch, Ute
    Adelman, Daniel C.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (02) : 384 - 386
  • [38] Second-line therapy for small-cell lung cancer
    Schmittel, Alexander
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (04) : 631 - 637
  • [39] Irinotecan as a Second-line Monotherapy for Small Cell Lung Cancer
    Sevinc, Alper
    Kalender, Mehmet Emin
    Altinbas, Mustafa
    Ozkan, Metin
    Dikilitas, Mustafa
    Camci, Celalettin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (04) : 1055 - 1059
  • [40] Second-line chemotherapy for relapsed small cell lung cancer
    Ebi, N
    Kubota, K
    Nishiwaki, Y
    Hojo, F
    Matsumoto, T
    Kakinuma, R
    Ohmatsu, H
    Sekine, I
    Yokosaki, M
    Gotoh, K
    Yamamoto, H
    Kodama, T
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1997, 27 (03) : 166 - 169
12345